Sarepta Therapeutics, Inc. insider trading
This tab shows only the shares insiders bought or sold on the open market in the last twelve months (Form 4 codes P and S). Grants, option exercises, shares held back for tax and gifts are left out on purpose, so what is left is insiders trading at the market price like anyone else.
In the last twelve months insiders at Sarepta Therapeutics, Inc. filed 2 open-market sales worth $417,410 and 0 open-market purchases, on Form 4 with the SEC. The latest: Mayo Stephen, Director, sold 7,239 shares at $17.02 on 12 March 2026, filed 13 March 2026.
| Traded | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 12 March 2026 | Mayo Stephen | Director | Sale | 7,239 | $17.02 | $123,208 | Form 4 |
| 16 December 2025 | Estepan Ian Michael | Chief Operating Officer | Sale | 13,187 | $22.31 | $294,202 | Form 4 |
A filing with several lines appears once per line.
Source
Form 4 filings on EDGAR for Sarepta Therapeutics, Inc.: the company's filing index.
The same record on your computer
GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.